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umor necrosis factor alfa (TNF-a) antagonists
are commonly used to treat inflammatory
disorders and are considered particularly
effective in the treatment of moderate to severe
psoriasis. Paradoxically, however, new-onset occur-
rence orworsening of psoriasis has been increasingly
recognized among patients treated with TNF-a
antagonists. We report on a 60-year-old man who
developed a severe psoriatic condition with diffuse
alopecia during infliximab therapy for psoriasis,
resulting in the discontinuation of infliximab.
Lymphocyte transportation test (LTT) results were
positive. Currently, there are few reports of LTT-
positive cases that are related to paradoxical
reactions by TNF-a antagonists. We discuss the
relationship between paradoxical reaction and the
mechanisms of LTT.
CASE REPORT
Before admittance to our clinic, a 60-year-old man
with a 7-year history of psoriasis vulgaris received
treatment consisting of topical steroids, topical
vitamin D analogs, ultraviolet therapy, and cyclo-
sporine at 2 different hospitals. Because his psoriasis
showed no signs of improvement from these treat-
ments, in May 2013 he received 5 mg/kg of inflix-
imab at weeks 0, 2, and 6. One and a half months
after the initiation of the infliximab treatment, pru-
ritic scaly plaques developed on his trunk. After
another 2 weeks, he became erythrodermic over his
entire body (Fig 1, A and B). He showed diffusethe Department of Dermatology, Sapporo Medical University
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observed on the palms and soles (Fig 1, C and D).
A skin biopsy specimen showed psoriasiform
epidermal hyperplasia with hyperkeratosis and para-
keratosis, telangiectasia, perivascular lymphocytic
infiltrate, and a small number of eosinophils in the
papillary dermis (Fig 2).
Serologic analysis found eosinophilia (total white
blood cells 8 3 103/L with 15.2% eosinophils). LTT
was performed twice. The stimulation index (SI) was
237% (normal range, \180%) at the second week
after the rashes appeared and 183% at the fourth
month. Consequently, an infliximab-induced para-
doxical reaction was diagnosed.
Infliximab was discontinued, and treatment with
topical steroids and maxacalcitol commenced.
However, there was no response to the topical
therapies, and cyclosporine was subsequently
started (2.5 mg/kg/d). Marked improvement was
observed immediately, and the psoriasiform erup-
tion disappeared after 9 months. Complete hair
regrowth was observed after 12 weeks. The cyclo-
sporine dosage was tapered to 1.5 mg/kg/d, and
there has been no recurrence to date (November
2014).JAAD Case Reports 2015;1:230-3.
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Fig 1. Clinical appearance on admission. A, Face. B, Body. C, Scaly erythema associated with
alopecia. D, The right sole.
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If successfully used, TNF-a antagonists can lead to
significant improvement of disease activity in pa-
tients with a variety of autoimmune diseases and
inflammatory disorders, particularly psoriasis.
However, in recent years, there have been increasing
reports of induced or exacerbated psoriasis among
patients receiving anti TNF-a therapy.
These adverse reactions have been noted in all
TNF-a inhibitors and have occurred in patients with
any disease in which these agents are used as
treatment. The incidence of TNF-a inhibitore
induced psoriasis has been estimated at 1.5% to
5%.1,2 Duration of therapy before onset or worsening
of psoriasis has ranged from 2 weeks to 48 months.3Interestingly, rash prognosis varies widely accord-
ing to individual cases. Collamer et al4 analyzed 114
cases of paradoxical psoriasis, among which most
patients (61%) were able to continue TNF-a antag-
onist therapy. However, 25% had to discontinue
treatment, and somewho later resumed therapy with
the same agent or another TNF-a inhibitor suffered
relapses.
The mechanism of TNF-a inhibitoreinduced par-
adoxical psoriasis remains unclear. The most widely
accepted hypothesis suggests there is an interaction
between TNF-a and interferon alfa (IFN-a). IFN-a is
an important cytokine that controls natural immunity
and is mainly produced from plasmacytoid dendritic
cells through stimuli such as infection or trauma.
Fig 2. Histologic specimen. Psoriasiform epidermal hy-
perplasia, telangiectatic blood vessels, perivascular lym-
phocytic infiltrate, and a small number of eosinophils in
the papillary dermis. (Hematoxylin-eosin stain; original
magnification: 340.)
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phase of psoriatic induction.5,6 TNF-a negatively
regulates IFN-a production.7 Therefore, antieTNF-a
therapy could increase IFN-a expression at the tissue
level and induce psoriasis. Seneschal et al8 found a
stronger production of the human myxovirus resis-
tance protein 1 that represented a specific marker for
type I IFN signaling in psoriasiform eruptions under
TNF-a treatment.
There are cases that could continue using the
TNF-a antagonist or show improvement if treat-
ment were changed to other types of biologic
therapies such as antieinterleukin-12/23 antibodies
or antieinterleukin-17A antibodies.4 This finding
suggests that the increase of IFN-a may only be a
manifestation trigger, and the following course may
be the same as that of primary psoriasis. In addition,
there is a large time lag between administration and
development of psoriatic lesions. It is presumably
because the balance between TNF-a and IFN-a
varies among individuals. In addition, certain envi-
ronmental triggers (infections, ultraviolet irradia-
tion, trauma) may be involved in the development
of psoriasis.
The main mediator of adverse drug reactions is
typically lymphocytes. LTT is a test to identify
antigen-specific T cells to specific drugs in vitro.
The peripheral blood T cells are cultured with the
incriminated drug, and their subsequent prolifera-
tion was measured by harvesting 3H-thymidine. The
results were expressed as the SI (SI = counts per
minute with drug/without drug.)
Although there is no consensus about when
the test should be performed, Kano et al9 found
that LTT should be performedwithin 1week after the
onset of Stevens-Johnson syndrome or toxic
epidermal necrolysis and 5 to 8 weeks after the
onset of the cutaneous eruptions in cases of drug-induced hypersensitivity syndrome or drug reaction
with eosinophilia and systemic symptoms. This
finding suggests that regulatory T cells that increase
during the acute stage may play a role in the
suppression of T-cell proliferation in patients with
drug-induced hypersensitivity syndrome/drug reac-
tion with eosinophilia and systemic symptoms.9
There are no reports indicating LTT shows a false-
positive result in patients treated with anti-TNF
agents. Therefore, in this study, LTT was performed
at 2 weeks (the acute stage) and again at 4 months (at
the time in which the influence of this medicine was
expected to be negligible and return to the normal
upper limit).
The patient’s condition did not change even after
infliximab was discontinued, so cyclosporine treat-
ment commenced. Cyclosporine is an immune sup-
pressant and has been used to treat posteorgan
transplantation complications and autoimmune dis-
eases. The main role of this agent is to suppress T
cells. Recently, reports indicate that cyclosporine
has the capacity to affect antigen-presenting cells
such as B cells and dendritic cells. Tajima et al10
reported that cyclosporine reduces IFN-a produc-
tion from the CD11c subset of dendritic cells
infected with the Sendai virus. This study suggested
that cyclosporine plays a role in suppressing both
the courses of T cells and plasmacytoid dendritic
cells that produce IFN-a.
There are several reports of new-onset psoriasis
paradoxically following TNF-a antagonist therapy.
To our knowledge, this case is a rare example of
erythroderma associated with alopecia that devel-
oped during infliximab therapy and showed a pos-
itive LTT result. In cases such as these, exact
diagnosis and early treatment intervention are
necessary.
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